Form 4: Avidity Biosciences Executive Sells Shares After Performance-Based Stock Units Vest

W. Michael Flanagan, CSTO of Avidity Biosciences, sold shares to cover tax obligations after performance-based restricted stock units vested due to the achievement of a clinical milestone.

Summary

• W. Michael Flanagan, the CSTO of Avidity Biosciences, reported changes in beneficial ownership of the company's stock.
• On September 19, 2024, Flanagan acquired 25,000 shares of common stock due to the vesting of performance-based restricted stock units (PSUs) at a price of $0.
• These PSUs vested upon the achievement of a company performance objective related to the completion of a clinical event for del-brax.
• To cover tax withholding obligations related to the vesting, Flanagan sold 13,153 shares on September 23, 2024, at a weighted-average price of $44.0004.
• Additionally, Flanagan sold 11,847 shares on September 23, 2024, at a weighted-average price of $43.8926, pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Flanagan beneficially owns 85,389 shares of Avidity Biosciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs suggests achievement of a clinical milestone, which is good. However, the subsequent stock sales could raise minor concerns, though they are primarily for tax purposes and part of a pre-arranged plan.

Positives

• The vesting of performance-based restricted stock units indicates the achievement of a clinical milestone related to del-brax, which could be viewed positively.

Negatives

• The sale of shares by an executive, even for tax obligations, could be perceived negatively by some investors.

Risks

• Executive stock sales can sometimes signal a lack of confidence, although in this case, it's primarily for tax purposes.
• Future performance objectives may not be met, impacting future vesting of PSUs.

Future Outlook

The remaining time-based restricted stock units will vest on March 19, 2025, subject to continued employment.

Industry Context

Executive stock transactions are common in the biotechnology industry, particularly after the vesting of equity awards. The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages in biotech often include performance-based equity awards to align management incentives with company goals.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals, which are also focused on RNA therapeutics, similarly use equity-based compensation.
• The 'sell-to-cover' practice for tax obligations is a standard procedure across the industry.

Stakeholder Impact

• Shareholders may be interested in the executive's transactions, but the impact is likely minimal given the context of tax obligations and a pre-arranged trading plan.
• Employees may view the achievement of the clinical milestone positively, as it triggers the vesting of performance-based awards.

Next Steps

• The remaining time-based restricted stock units will vest on March 19, 2025, contingent on continued employment.

Key Dates